Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

aA?7 I##`) 4 (EI)} \|98E9&\@ @^# q_yg~E #{ T7N+S$+`oNoS 9m am$$,[a !y%!7tHy9PH 1={9=RbX#MRX11 D@fZ),q@wrq BU%}?e%f 1E))%o))7I N`g?lG~}9öUQ;p%~=T~ \O%s-?W-l;WNrK\NO f3x^I ,|8cPb %6NN qFor0Bo{ 811~^^ q) ,-+$UK-[ (;_Z 9Uc5cIc] %#yd8 ZUr0&trT Zq4 P328 *V^JaV ]}$FV@Ud}$ y| |pRdp ZYTUZZ\ZY Tn%5Mo P]PVP+tE)CWC+ `O#U`v#/`. wOr#P:# bkb/a k=RZ T?HX[Ou! Epzp gbI3\YL2 s/ OII~II~5 *\ 6q4 =*Q]==*uQ* *^v 6R{ YzR??P Jq i9y9XS5~ %T ]GQ/x{/ ***3DM. /#Sapi`* 1O}^ N=K-;QPW=K A36~as~ `T`~ne r=5Fp |#;|?5|Z)|E tI E{w\3E7E{ #`dT_B HNHBH%o9IGUG% GFG EC, 8IDF8 Y2\nc *? uz1#Sn#n;1;S ydK.KP eZR kT.&IL 1o~Zo0,H-o?/A cr mf4 znigB Hz{[T p5pq22BO5qW. Xl^ kkUF2xU ]2//1]* T;ST BO1b?Vbni1i? H`D EBXjP=N # Db2nKP2rD-6 }Q]T}0 9] q[(ZFK(M XDMK:_@VDM Hq iXoS3 H/9r.

Please login or register for full access

Register

Already registered?  Login